Idenix Pharmaceuticals commenced an underwritten registered public offering of $150 million of its common stock. Alnylam Pharmaceuticals will do exactly the same thing, although probably at a much deeper discount and this could come at any time since they already have their earnings data for the quarter which ended on July 30th. It's probably set on automatic if the stock price begins to fall, sort of a double-whammy. The insiders tell you what to do, they all sold their acquired compensation shares at the peak. You should follow their example or you just give away your profits to the swing traders.